Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)

Rania S. Khelifi, Steven J.T. Huang, BMLSc, Kerry J. Savage, MDMSc, Diego Villa, MDMPH, David W. Scott, MBChB, PhD, Khaled Ramadan, MBBCH, MRCP, FRCPath, Joseph M. Connors, MD, Laurie H. Sehn, MDMPH, Cynthia L Toze, MD FRCPC, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138887

Published: 2020

Journal Articles

Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma

Katsuyoshi Takata, MD PhD, Tomohiro Aoki, MD PhD, Lauren C. Chong, MSc, Katy Milne, Tomoko Miyata-Takata, MD PhD, Karanvir Singh, Talia Goodyear, Pedro Farinha, MD PhD, Graham W. Slack, MD, Laurie H. Sehn, MDMPH, Kerry J. Savage, MDMSc, Brad H Nelson, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-141462

Published: 2020

Journal Articles

Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

Sarah E. Perry, MD MSc, Derrick G. Lee, PhD, Ciara L. Freeman, MSc, MBBChir, Diego Villa, MDMPH, Alina S. Gerrie, MD MPH, Pedro Farinha, MD PhD, Jeffrey W. Craig, MD PhD, Graham W. Slack, MD, Joseph M. Connors, MD, David W. Scott, MBChB, PhD, Kerry J. Savage, BSc, MD MSc, Laurie H. Sehn, MDMPH

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136457

Published: 2020

Journal Articles

Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada

Kai Zhu, Andrew Jamroz, Bsc, Steven J.T. Huang, BMLSc, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Graham W. Slack, MD, Laurie H. Sehn, MDMPH, Joseph M. Connors, MD, Cynthia L. Toze, MDFRCPC,MSc, Kerry J. Savage, MDMSc, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-141183

Published: 2020

Journal Articles

Characteristics and Treatment Outcomes of Plasmablastic Lymphoma in British Columbia (BC)

Nicole Chien, MBBChir, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, Graham W. Slack, MD, Kerry J. Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Laurie H. Sehn, MDMPH, Kevin W Song, MD FRCPC, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142351

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137078

Published: 2020

Journal Articles

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

William A. Wood, MD MPH, Donna S. Neuberg, ScD, John Colton Thompson, Martin S. Tallman, MD, Mikkael A. Sekeres, MD MS, Laurie H. Sehn, MDMPH, Kenneth Anderson, MD, Aaron D Goldberg, MDPhD, Nathan A Pennell, MD PhD, Charlotte M. Niemeyer, MD, Emily Tucker, MS, Kathleen Hewitt, DNP,CPHQ,AACC,RN, Robert M Plovnick, MD MS, Lisa K. Hicks, MD MSc

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141327

Published: 2020

Journal Articles

Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA

Alex F. Herrera, MD, Samuel Tracy, Brandon Croft, Stephen Opat, FRACP, FRCPA, MBBS, Jill Ray, Lisa Musick, Joseph N. Paulson, Laurie H. Sehn, MDMPH, Yanwen Jiang

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-136645

Published: 2020

Journal Articles

Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Kristin C. Marr, MD, Jonathan Simkin, MPH, Andrea C. Lo, MD, Joseph M. Connors, MD, Alina S. Gerrie, MD MPH, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Greg Hapgood, BMBS, FRACP, FRCPA, Laurie H. Sehn, MDMPH, Ryan Woods, MSc PhD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136454

Published: 2020

Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-135839

Published: 2020

Journal Articles

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn, MDMPH, Alex F. Herrera, MD, Matthew J Matasar, Manali Kamdar, Sarit Assouline, Mark Hertzberg, Tae Min Kim, Won-Seog Kim, Andrew McMillan, Muhit Özcan, Jamie M Hirata, Elicia Penuel, Ji Cheng, Grace Ku, Christopher R Flowers, MDMS

Blood (2018) 132 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2018-99-118551

Published: 2018

Journal Articles

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H Sehn, MDMPH, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin, FRCPC, MD MS

Blood (2018) 132 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2018-99-114913

Published: 2018

Journal Articles

Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing

Sally E Trabucco, BS, Ethan S Sokol, Jay A Moore, Sophia Maund, Garrett M Frampton, Vincent A Miller, Jeffrey Venstrom, Lee A Albacker, PhD, Laurie H Sehn, MDMPH, Mikkel Z Oestergaard, Christopher R Bolen

Blood (2018) 132 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2018-99-116677

Published: 2018

Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli

Blood (2018) 132 (Supplement 1): 783.

https://doi.org/10.1182/blood-2018-99-116845

Published: 2018

Journal Articles

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Blood (2018) 132 (Supplement 1): 921.

https://doi.org/10.1182/blood-2018-99-116827

Published: 2018

Journal Articles

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Anas Younes, MD, Laurie H Sehn, MDMPH, Peter Johnson, MD, Pier Luigi Zinzani, MD, Xiaonan Hong, MD, Jun Zhu, Olga Samoilova, MD, Cheolwon Suh, Itaru Matsumura, MD, Andres Lopez-Hernandez, MD, Ulrich Dührsen, Prof, MD PhD, Catherine Thieblemont, MD, Jodi Carey, BSN, RN, Grace Liu, PhD, S. Martin Shreeve, MD PhD, Steven Sun, PhD, Jessica Vermeulen, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 784.

https://doi.org/10.1182/blood-2018-99-112988

Published: 2018

Journal Articles

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Blood (2018) 132 (Supplement 1): 399.

https://doi.org/10.1182/blood-2018-99-118344

Published: 2018

Journal Articles

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Diego Villa, MD, Graham W Slack, MD PhD, Muntadhar Al-Moosawi, MD, Susana Ben-Neriah, BSc, Tamara Shenkier, MD, Joseph M. Connors, MD, Laurie H Sehn, MDMPH, Kerry J Savage, BSc, MD MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD, Randy D. Gascoyne, MD, King Tan, MD

Blood (2018) 132 (Supplement 1): 348.

https://doi.org/10.1182/blood-2018-99-114218

Published: 2018

Journal Articles

Prognostic Significance of MYC Single, Double, Triple Hit and MYC -Translocation Partner Status in Diffuse Large B-Cell Lymphoma - a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC)

Andreas Rosenwald, Laurie H Sehn, MDMPH, Delphine Maucort-Boulch, MD PhD

Blood (2018) 132 (Supplement 1): 344.

https://doi.org/10.1182/blood-2018-99-113368

Published: 2018

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

NARROW

Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)

Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma

Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada

Characteristics and Treatment Outcomes of Plasmablastic Lymphoma in British Columbia (BC)

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA

Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Prognostic Significance of MYC Single, Double, Triple Hit and MYC -Translocation Partner Status in Diffuse Large B-Cell Lymphoma - a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC)

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only